@article{f742f53d7bae4cceba20b6d2b5b3a273,
title = "Invasive fungal infections in solid organ transplant recipients",
abstract = "Invasive fungal infections are a major problem in solid organ transplant (SOT) recipients. Overall, the most common fungal infection in SOT is candidiasis, followed by aspergillosis and cryptococcosis, except in lung transplant recipients, where aspergillosis is most common. Development of invasive disease hinges on the interplay between host factors (e.g., integrity of anatomical barriers, innate and acquired immunity) and fungal factors (e.g., exposure, virulence and resistance to prophylaxis). In this article, we describe the epidemiology and clinical features of the most common fungal infections in organ transplantation. Within this context, we review recent advances in diagnostic modalities and antifungal chemotherapy, and their impact on evolving prophylaxis and treatment paradigms.",
keywords = "antifungal, aspergillosis, candidiasis, cryptococcosis, fungal, galactomannan, kidney transplant, liver transplant, lung transplant, transplant",
author = "Shmuel Shoham and Marr, {Kieren A.}",
note = "Funding Information: J. Gavald{\`a} has received grant support from Gilead, Pfizer and Instituto de Salud Carlos III. Y. Meije has no conflicts of interest. J. Fort{\'u}n has received grant support from Astellas Pharma, Gilead Sciences, Merck Sharp and Dohme, Pfizer and Instituto de Salud Carlos III in the past 5 years. He has been paid for talks on behalf of Gilead Sciences, Merck Sharp and Dohme, Pfizer, Astellas Pharma and Schering Plough. E. Roilides has received research support from Pfizer, Gilead, Merck and Schering. He has served on the speakers{\textquoteright} bureau of and has made contributions to advisory boards of Gilead, Astellas, Pfizer and Merck and has made contributions to their advisory boards. F. Saliba has received speaker fees and/or research funding from Novartis Astellas, Roche, Genzyme, MSD, Gilead, Pfizer Gambro and Vital Therapies. O. Lortholary has been a consultant for Gilead Sciences, and has received speaker fees from Pfizer, Merck, Gilead Sciences and Astellas. In the past 5 years, M. Cuenca-Estrella has received grant support from Astellas Pharma, bioMerieux, Gilead Sciences, Merck Sharp and Dohme, Pfizer, Schering Plough, Soria Melguizo SA, Ferrer International, the European Union, the ALBAN programme, the Spanish Agency for International Cooperation, the Spanish Ministry of Culture and Education, the Spanish Health Research Fund, the Instituto de Salud Carlos III, the Ramon Areces Foundation and the Mutua Madrile{\~n}a Foundation. He has been an advisor/consultant to the Panamerican Health Organization, Astellas Pharma, Gilead Sciences, Merck Sharp and Dohme, Pfizer and Schering Plough. He has been paid for talks on behalf of Gilead Sciences, Merck Sharp and Dohme, Pfizer, Astellas Pharma and Schering Plough. P. Mu{\~n}oz has received speaker fees, grant support and consultancy fees from Astellas, Gilead, Pfizer and Novartis. P. Grossi has no conflicts of interest.",
year = "2012",
month = may,
doi = "10.2217/fmb.12.28",
language = "English (US)",
volume = "7",
pages = "639--655",
journal = "Future microbiology",
issn = "1746-0913",
publisher = "Future Medicine Ltd.",
number = "5",
}